Importantly, some of these agents have progressed from preclinical research to clinical trials, showing promise of developing effective cancer therapeutics targeting the SWI/SNF complex functions (Dreier et al., 2024; Malone & Roberts, 2024). The gene discussed is SMARCA1; the disease is cancer.